Urology
Volume 75, Issue 2 , Pages 454-459 , February 2010

Serum Level of Clusterin and Its Density in Men with Prostate Cancer as Novel Biomarkers Reflecting Disease Extension

Received 20 June 2009 ,Accepted 10 August 2009.

References 

  1. Trougakos IP, Gonos ES. Clusterin/apolipoproyein J in human aging and cancer. Int J Biochem Cell Biol. 2002;34:1430–1448
  2. Gleave M, Chi KN. Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers. Ann NY Acad Sci. 2005;1058:1–15
  3. Miyake H, Hara I, Gleave ME. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. Int J Urol. 2005;12:785–794
  4. Miyake H, Hara I, Fujisawa M, et al. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer. Expert Opin Investig Drugs. 2006;15:507–517
  5. Steinberg J, Oyasu R, Lang S, et al. Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res. 1997;3:1707–1711
  6. July LV, Akbari M, Zellweger T, et al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate. 2002;50:179–188
  7. Pins MR, Fiadjoe JE, Korley F, et al. Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Prostate Cancer Prostatic Dis. 2004;7:243–248
  8. Miyake H, Muramaki M, Kurahashi T, et al. Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy. Urology. 2006;68:609–614
  9. Miyake H, Yamanaka K, Muramaki M, et al. Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. Oncol Rep. 2005;14:1371–1375
  10. Doustjalali SR, Yusof R, Yip CH, et al. Aberrant expression of acute-phase reactant proteins in sera and breast lesions of patients with malignant and benign breast tumors. Electrophoresis. 2004;25:2392–2401
  11. Stejskal D, Fiala RR. Evaluation of serum and urine clusterin as a potential tumor marker for urinary bladder cancer. Neoplasma. 2006;53:343–346
  12. Miyake H, Harada K, Inoue T, et al. Additional sampling of the dorsal apex on systematic prostate biopsy: impact on early detection of prostate cancer. Urology. 2007;69:738–742
  13. Redondo M, Villar E, Torres-Muñoz J, et al. Overexpression of clusterin in human breast carcinoma. Am J Pathol. 2000;157:393–399
  14. Kurahashi T, Muramaki M, Yamanaka K, et al. Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. BJU Int. 2005;96:895–899
  15. Xie D, Lau SH, Sham JS, et al. Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma. Cancer. 2005;103:277–283
  16. Watari H, Ohta Y, Hassan MK, et al. Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. Gynecol Oncol. 2008;108:527–532
  17. Ravery V, Chastang C, Toublanc M, et al. Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer. Eur Urol. 2000;37:449–455
  18. Wang L, Hricak H, Kattan MW, et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology. 2006;238:597–603
  19. Ohori M, Kattan MW, Koh H, et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol. 2004;171:1844–1849
  20. Gao X, Ren S, Lu X, et al. The newer the better? (Comparison of the 1997 and 2001 partin tables for pathologic stage prediction of prostate cancer in China). Urology. 2008;72:1096–1101
  21. Quinn DI, Henshall SM, Haynes AM, et al. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol. 2001;19:3692–3705
  22. Karakiewicz PI, Eastham JA, Graefen M, et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology. 2005;66:1245–1250
  23. Chi KN, Siu LL, Hirte H, et al. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res. 2008;14:833–839
  24. Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst. 2005;97:1287–1296

PII: S0090-4295(09)02380-2

doi: 10.1016/j.urology.2009.08.029

Urology
Volume 75, Issue 2 , Pages 454-459 , February 2010

Article Tools

* Image Usage & Resolution